Transplantation of Human Amniotic Membrane over the Liver Surface Reduces Hepatic Fibrosis in a Cholestatic Model in Young Rats

Abstract EN

Purpose. Biliary atresia precedes liver cirrhosis and liver transplantation.

Amniotic membrane (AM) promotes tissue regeneration, inhibits fibrosis, and reduces inflammation.

Here, we test amniotic membrane potential as a therapeutic tool against cholestatic liver fibrosis.

Methods.

Three groups of rats were used: sham surgery (SS), bile duct ligature (BDL), and bile duct ligature plus human amniotic membrane (BDL + AM).

After surgery, animals were sacrificed at different weeks.

Biochemical and histopathological analyses of liver tissue were performed.

Collagen was expressed as a percentage of total liver tissue area.

qPCR was performed to analyse gene expression levels of transforming growth factor-β1 (Tgfb1) and apelin (Apln).

Statistical analysis performed considered p<0.05 was significant.

Results. Groups undergoing BDL developed cholestasis.

Biochemical markers from BDL + AM group improved compared to BDL group.

Ductular reaction, portal fibrosis, and bile plugs were markedly reduced in the BDL + AM group compared to BDL group.

Collagen area in BDL + AM group was statistically decreased compared to BDL group.

Finally, expression levels of both Apln and Tgfb1 mRNA were statistically downregulated in BDL + AM group versus BDL group.

Conclusion.

AM significantly reduces liver fibrosis in a surgical animal model of cholestasis.

Our results suggest that AM may be useful as a therapeutic tool in liver cirrhosis.